CoVaRR-Net Funded Research Results

CoVaRR-Net Funded Research Results2022-08-09T12:55:08-04:00

People with Human Immunodeficiency Virus receiving suppressive antiretroviral therapy show typical antibody durability after dual coronavirus disease 2019 vaccination and strong third dose responses

June 12, 2024|Funded Research Results, Pillar 1|

This study investigates the humoral immune responses of people living with HIV (PLWH) on suppressive antiretroviral therapy (ART) for up to 6 months post second dose and one month post third doses of the COVID-19 vaccine.

The RNA interference effector protein Argonaute 2 functions as a restriction factor against SARS-CoV-2

May 23, 2024|Funded Research Results, Pillar 4|

Plants, insects, and invertebrates defend against virus infections by using an RNA based system, called RNA interference or RNAi. RNAi uses small pieces of the viral genome, termed small interfering RNAs (siRNAs) to target and destroy infectious viral genomes by using a protein that cleaves RNA, called Argonaute.

Go to Top